These observations are now being taken further along the road to clinical evaluation and a small Phase I clinical trial has been reported where a DC vaccine loaded with 100mer TR MUC1 peptide carrying Tn was administered with KLH to non-metastatic, castrate-resistant prostate cancer patients [52]. Here, MUC1 is linked to Familial prostate cancer.